The Markowitz Lab at
The Markowitz Lab at
Dr. Markowitz is a physician scientist, U.S. Board certified internist, medical oncologist, and clinical informaticist. His laboratory focuses on the nitric oxide (NO) mechanisms of inhibition to checkpoint blockade therapy in melanoma patients. In addition, the lab is developing tools to predict which patients are likely to fail immune-based therapy via novel high dimensional flow cytometric, mass spectrometry and informatics techniques, allowing those patients to be treated with other potentially more effective therapies.
Dr. Markowitz’s earned his B.A. in Biochemistry, his M.S. in Chemistry, and his Ph.D. in Biochemistry. He completed an Internal Medicine Residency, a Medical Oncology Fellowship, and a Postdoctoral Fellowship in Immunology. Dr. Markowitz is striving to translate the knowledge gained in the laboratory to the clinic via his unique combination of clinical and research skills. At Moffitt, his group has also translated preclinical work into a first-in-human clinical trial. In addition, Dr. Markowitz is the Principal Investigator on multiple translational and clinical protocols to investigate the mechanisms of resistance to checkpoint blockade in melanoma patients.
LinkedIn: Joseph Markowitz
Department of Cutaneous Oncology
H. Lee Moffitt Cancer Center & Research Institute
Department of Oncologic Sciences
Morsani College of Medicine
University of South Florida
Chris has been with Moffitt since 2018. He earned his B.S. in Biomedical Science from Eckerd College and his M.S. in Medical Sciences from the University of South Florida Morsani College of Medicine. Chris is currently studying nitric oxide within immune cell phenotypes that contribute to immune therapy resistance.
LinkedIn: Christopher Dukes
John joined the lab for a Summer 2022 internship. He earned his B.S. in Interdisciplinary Studies from the University of Central Florida and is currently pursuing his M.D. at the University of South Florida Morsani College of Medicine. He is working to understand the nitric oxide related metabolites in melanoma.
